{"groups":[{"description":"Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.\n\nDoxorubicin: given IV\n\nBleomycin: given IV\n\nVinblastine: given IV\n\nDacarbazine: given IV\n\nRadiotherapy","id":"FG000","title":"Arm A (ABVD)"},{"description":"Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide \\[375 mg/m²\\] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.\n\nDoxorubicin: given IV\n\nBleomycin: given IV\n\nVinblastine: given IV\n\nVincristine: given IV\n\nMechlorethamine: given IV\n\nEtoposide: given IV\n\nPrednisone: taken orally\n\nCyclophosphamide: given IV\n\nRadiotherapy","id":"FG001","title":"Arm B (Stanford V)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Alternative therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"21"}],"type":"Off-treatment reason missing"},{"reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"27"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"428"},{"groupId":"FG001","numSubjects":"426"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"414"},{"groupId":"FG001","numSubjects":"422"}],"type":"Treated Pts w/ Toxicity Data Available"},{"achievements":[{"groupId":"FG000","numSubjects":"395"},{"groupId":"FG001","numSubjects":"399"}],"type":"Eligible Patients"},{"achievements":[{"groupId":"FG000","numSubjects":"330"},{"groupId":"FG001","numSubjects":"366"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"60"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between April 22, 1999 and June 15, 2006, 854 participants were enrolled. The first patient accrued was on June 17, 1999."}